Last reviewed 2026-04-23 · How we verify

ES102

Elpiscience Biopharma, Ltd. · Phase 2 active Small molecule

At a glance

Generic name	ES102
Sponsor	Elpiscience Biopharma, Ltd.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer (PHASE2)
A Study of ES102 (OX40 Agonist) in Patients With Advanced Solid Tumors (PHASE1)
A Study of ES102 (OX40 Agonist) in Combination With JS001 in Patients With Advanced Solid Tumors (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results